MedKoo Cat#: 558683 | Name: RIPGBM
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RIPGBM is a cell type-selective apoptosis inducer in glioblastoma multiforme (GBM) cancer stem cells (CSCs).

Chemical Structure

RIPGBM
RIPGBM
CAS#355406-76-7

Theoretical Analysis

MedKoo Cat#: 558683

Name: RIPGBM

CAS#: 355406-76-7

Chemical Formula: C26H21FN2O3

Exact Mass: 428.1536

Molecular Weight: 428.46

Elemental Analysis: C, 72.89; H, 4.94; F, 4.43; N, 6.54; O, 11.20

Price and Availability

Size Price Availability Quantity
5mg USD 400.00
10mg USD 700.00
25mg USD 1,250.00
50mg USD 2,300.00
100mg USD 4,000.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RIPGBM
IUPAC/Chemical Name
N-(3-(Benzylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-N-(4-fluorobenzyl)acetamide
InChi Key
COATXBHZYVUJQP-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H21FN2O3/c1-17(30)29(16-19-11-13-20(27)14-12-19)24-23(28-15-18-7-3-2-4-8-18)25(31)21-9-5-6-10-22(21)26(24)32/h2-14,28H,15-16H2,1H3
SMILES Code
CC(N(C(C1=O)=C(NCC2=CC=CC=C2)C(C3=C1C=CC=C3)=O)CC4=CC=C(F)C=C4)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
RIPGBM is a selective inducer of apoptosis in GBM CSCs with an EC50 of ≤500 nM.
In vitro activity:
To be determined
In vivo activity:
In an orthotopic intracranial GBM CSC tumor xenograft mouse model, RIPGBM significantly suppressed tumor formation in vivo. Reference: Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440. https://pubmed.ncbi.nlm.nih.gov/30846550/
Solvent mg/mL mM
Solubility
DMSO 33.3 77.79
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 428.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. West TJ, Bi J, Martínez-Peña F, Curtis EJ, Gazaniga NR, Mischel PS, Lairson LL. A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death. J Am Chem Soc. 2023 Apr 5. doi: 10.1021/jacs.2c11715. Epub ahead of print. PMID: 37017374. 2. Lucki NC, Villa GR, Vergani N, Bollong MJ, Beyer BA, Lee JW, Anglin JL, Spangenberg SH, Chin EN, Sharma A, Johnson K, Sander PN, Gordon P, Skirboll SL, Wurdak H, Schultz PG, Mischel PS, Lairson LL. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440. doi: 10.1073/pnas.1816626116. Epub 2019 Mar 7. PMID: 30846550; PMCID: PMC6442583.
In vitro protocol:
To be determined
In vivo protocol:
1. West TJ, Bi J, Martínez-Peña F, Curtis EJ, Gazaniga NR, Mischel PS, Lairson LL. A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death. J Am Chem Soc. 2023 Apr 5. doi: 10.1021/jacs.2c11715. Epub ahead of print. PMID: 37017374. 2. Lucki NC, Villa GR, Vergani N, Bollong MJ, Beyer BA, Lee JW, Anglin JL, Spangenberg SH, Chin EN, Sharma A, Johnson K, Sander PN, Gordon P, Skirboll SL, Wurdak H, Schultz PG, Mischel PS, Lairson LL. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440. doi: 10.1073/pnas.1816626116. Epub 2019 Mar 7. PMID: 30846550; PMCID: PMC6442583.
1: Lucki NC, Villa GR, Vergani N, Bollong MJ, Beyer BA, Lee JW, Anglin JL, Spangenberg SH, Chin EN, Sharma A, Johnson K, Sander PN, Gordon P, Skirboll SL, Wurdak H, Schultz PG, Mischel PS, Lairson LL. A cell type-selective apoptosis- inducing small molecule for the treatment of brain cancer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440. doi: 10.1073/pnas.1816626116. Epub 2019 Mar 7. PMID: 30846550; PMCID: PMC6442583. 2: West TJ, Bi J, Martínez-Peña F, Curtis EJ, Gazaniga NR, Mischel PS, Lairson LL. A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death. J Am Chem Soc. 2023 Apr 5:10.1021/jacs.2c11715. doi: 10.1021/jacs.2c11715. Epub ahead of print. PMID: 37017374; PMCID: PMC10551045.